CO2020014677A2 - Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes - Google Patents
Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunesInfo
- Publication number
- CO2020014677A2 CO2020014677A2 CONC2020/0014677A CO2020014677A CO2020014677A2 CO 2020014677 A2 CO2020014677 A2 CO 2020014677A2 CO 2020014677 A CO2020014677 A CO 2020014677A CO 2020014677 A2 CO2020014677 A2 CO 2020014677A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- isoindolylquinoline
- pyrazino
- tetrahydro
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (I), en donde R1 a R6, m y n son como se describen en el presente documento, a una sal farmacéuticamente aceptable, enantiómero o diastereómero de aquellos, y a composiciones que incluyen los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018090004 | 2018-06-05 | ||
EP18193916 | 2018-09-12 | ||
CN2019086019 | 2019-05-08 | ||
PCT/EP2019/064323 WO2019233941A1 (en) | 2018-06-05 | 2019-06-03 | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020014677A2 true CO2020014677A2 (es) | 2020-12-10 |
Family
ID=66793968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0014677A CO2020014677A2 (es) | 2018-06-05 | 2020-11-26 | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210371432A1 (es) |
EP (1) | EP3802539B1 (es) |
JP (1) | JP7374130B2 (es) |
KR (1) | KR20210018818A (es) |
CN (1) | CN112204028B (es) |
AU (1) | AU2019280728A1 (es) |
BR (1) | BR112020024782A2 (es) |
CA (1) | CA3098291A1 (es) |
CL (1) | CL2020003065A1 (es) |
CO (1) | CO2020014677A2 (es) |
CR (1) | CR20200584A (es) |
IL (1) | IL279144A (es) |
MA (1) | MA52747A (es) |
MX (1) | MX2020012827A (es) |
PE (1) | PE20210131A1 (es) |
PH (1) | PH12020552092A1 (es) |
SG (1) | SG11202011137SA (es) |
TW (1) | TW202016111A (es) |
WO (1) | WO2019233941A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230002375A1 (en) * | 2019-11-12 | 2023-01-05 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
WO2021099284A1 (en) * | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
WO2021099285A1 (en) * | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Triazatricycle compounds for the treatment of autoimmune disease |
CN115835910A (zh) | 2020-07-14 | 2023-03-21 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢化异喹啉或氢化萘啶化合物 |
WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
CN114057759B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
AU2021385752A1 (en) * | 2020-11-26 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
WO2023025109A1 (zh) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
CN114656363A (zh) * | 2022-03-28 | 2022-06-24 | 南京林业大学 | 一种钯催化芳香酯类化合物的合成方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
SI3057964T1 (sl) | 2013-10-14 | 2020-03-31 | Eisai R&D Management Co., Ltd. | Selektivno substituirane spojine kinolina |
SG10202001146PA (en) | 2015-12-17 | 2020-03-30 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
RU2758686C2 (ru) * | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
-
2019
- 2019-06-03 MA MA052747A patent/MA52747A/fr unknown
- 2019-06-03 PE PE2020001875A patent/PE20210131A1/es unknown
- 2019-06-03 JP JP2020567772A patent/JP7374130B2/ja active Active
- 2019-06-03 MX MX2020012827A patent/MX2020012827A/es unknown
- 2019-06-03 CA CA3098291A patent/CA3098291A1/en active Pending
- 2019-06-03 KR KR1020207034855A patent/KR20210018818A/ko unknown
- 2019-06-03 EP EP19729220.4A patent/EP3802539B1/en active Active
- 2019-06-03 US US16/972,556 patent/US20210371432A1/en active Pending
- 2019-06-03 CR CR20200584A patent/CR20200584A/es unknown
- 2019-06-03 WO PCT/EP2019/064323 patent/WO2019233941A1/en unknown
- 2019-06-03 BR BR112020024782-0A patent/BR112020024782A2/pt not_active Application Discontinuation
- 2019-06-03 CN CN201980035182.7A patent/CN112204028B/zh active Active
- 2019-06-03 AU AU2019280728A patent/AU2019280728A1/en not_active Abandoned
- 2019-06-03 SG SG11202011137SA patent/SG11202011137SA/en unknown
- 2019-06-04 TW TW108119369A patent/TW202016111A/zh unknown
-
2020
- 2020-11-25 CL CL2020003065A patent/CL2020003065A1/es unknown
- 2020-11-26 CO CONC2020/0014677A patent/CO2020014677A2/es unknown
- 2020-12-01 IL IL279144A patent/IL279144A/en unknown
- 2020-12-04 PH PH12020552092A patent/PH12020552092A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3802539A1 (en) | 2021-04-14 |
EP3802539B1 (en) | 2023-09-20 |
CL2020003065A1 (es) | 2021-04-30 |
CN112204028A (zh) | 2021-01-08 |
PH12020552092A1 (en) | 2021-05-31 |
MA52747A (fr) | 2021-04-14 |
CA3098291A1 (en) | 2019-12-12 |
AU2019280728A1 (en) | 2020-11-12 |
PE20210131A1 (es) | 2021-01-19 |
IL279144A (en) | 2021-01-31 |
EP3802539C0 (en) | 2023-09-20 |
US20210371432A1 (en) | 2021-12-02 |
KR20210018818A (ko) | 2021-02-18 |
MX2020012827A (es) | 2021-02-15 |
JP2021527041A (ja) | 2021-10-11 |
BR112020024782A2 (pt) | 2021-03-02 |
JP7374130B2 (ja) | 2023-11-06 |
CN112204028B (zh) | 2023-12-29 |
SG11202011137SA (en) | 2020-12-30 |
TW202016111A (zh) | 2020-05-01 |
WO2019233941A1 (en) | 2019-12-12 |
CR20200584A (es) | 2021-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
CO2017007355A2 (es) | Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b | |
CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
CR20190087A (es) | Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica | |
CO6531444A2 (es) | Métodos sintéticos para compuestos espiro-oxoindol | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
CL2017002745A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
DOP2017000034A (es) | Compuestos de imidazopiridazina | |
CL2020002139A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
CL2022000802A1 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CL2017002651A1 (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer | |
CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
ECSP20008530A (es) | Novedosos compuestos que activan la ruta nrf2 | |
CO2024006398A2 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
CO2017003225A2 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos | |
EA201790231A1 (ru) | Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза |